What’s next for inherited retinal disease (IRD) treatments? In this episode of the EURETINA IME video interview series, Profs. Bart Leroy and Hélène Dollfus explore the latest innovations shaping the future of IRD care.

From gene-specific therapies targeting precise mutations to broader approaches designed to address multiple genes or underlying mechanisms, they unpack the potential of cutting-edge strategies. The discussion also includes an overview of ongoing cell therapy clinical trials and a candid look at the gaps in current clinical care pathways that need urgent attention.

Stay informed about the future of IRD treatment—watch this episode and explore the entire series!

Independent medical education supported by Johnson & Johnson, Neurotech Pharmaceuticals, and Alkeus Pharmaceuticals.